21st June 2024

A patient is embarking on a course of first line anti-tuberculous therapy

A patient is embarking on a course of first line anti-tuberculous therapy (rifampicin, isoniazid, pyrazinamide, ethambutol) for a diagnosis of pulmonary tuberculosis. Early phenotypic testing has returned by the time the patient returns for their first clinic visit. She reports an improvement in her symptoms. A plain film of the patient’s chest shows interval improvement in the consolidation originally visualised in her left upper lobe. The report for the phenotypic sensitivities is provided below:

Rifampicin: Susceptible

Isoniazid: Resistant

Pyrazinamide: Susceptible

Ethambutol: Susceptible

What is the best course of action with respect to the patient’s treatment regimen?

Select the SINGLE most appropriate option from the list below. Select ONE option only.